Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1335324 | 0.88 | KMT2A (0.46) | TSHRKMT2ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL1070965 | 0.84 | SMN1; SMN2 (0.49) | TSHRKMT2ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL1584481 | 0.84 | TSHR (0.46) | TSHRKMT2ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL31284435 | 0.83 | SMN1; SMN2 (0.41) | TSHRKMT2ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL31452008 | 0.83 | SMN1; SMN2 (0.41) | TSHRKMT2ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL31285049 | 0.83 | SMN1; SMN2 (0.41) | TSHRKMT2ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL27750330 | 0.83 | TSHR (0.49) | TSHRKMT2ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL23985860 | 0.82 | TSHR (0.51) | TSHRKMT2ASMN1; SMN2TDP1LMNA | |
| SCHEMBL5310060 | 0.81 | KMT2A (0.47) | TSHRKMT2ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL13520113 | 0.81 | TDP1 (0.50) | TSHRKMT2ASMN1; SMN2MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4652154-A1 | NOVEL ALPK1 INHIBITORS | Pyrotech (Beijing) Biotechnology Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025060978-A1 | TRICYCLIC PYRIDINE COMPOUND ACTING AS SARM1 ENZYME ACTIVITY INHIBITOR, AND USE THEREOF | 科辉智药(深圳)新药研究中心有限公司 | 2025-03-27 | — | — | WO | disclosed |
| EP-4499630-A1 | BCL-XL INHIBITORS | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| CN-118974033-A | Bcl-xL inhibitors | 百济神州有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024153225-A1 | NOVEL ALPK1 INHIBITORS | PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD. (CN) | 2024-07-25 | — | — | WO | disclosed |
| WO-2023185986-A1 | BCL-XL INHIBITORS | BEIGENE , LTD. (KY) | 2023-10-05 | — | — | WO | disclosed |
| CN-1759118-B | Diazepinoindole derivatives as kinase inhibitors | PFIZER | 2010-12-08 | — | — | CN | disclosed |
| US-7462713-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462713-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1947102-A1 | Compositions comprising diazepinoindole derivatives as kinase inhibitors | Pfizer, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007047646-A2 | SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047646-A2 | SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| CN-1759118-A | Diazepinoindole derivatives as kinase inhibitors | PFIZER (US) | 2006-04-12 | — | — | CN | disclosed |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034128-A1 | BCL-XL INHIBITORS | BCL2, BCL2L1, BCL2L10 | TSHR 3890/4885KMT2A 3308/4885SMN1; SMN2 3443/4885 |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK2, CHEK1, CHKA | TSHR 2085/4885KMT2A 1977/4885SMN1; SMN2 3537/4885 |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | MAP3K20, MAP3K3, MAP3K19 | TSHR 3460/4885KMT2A 1591/4885SMN1; SMN2 3486/4885 |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | CHEK1, CHEK2, CHKA | TSHR 1995/4885KMT2A 1951/4885SMN1; SMN2 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.